Gravitas Therapeutics (BAL2062) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Gravitas Therapeutics (BAL2062) General Information

Description

Portfolio of a BAL2062 compound based in United States. The compound is a novel clinical-stage antifungal agent for the treatment of immunocompromised patients with serious fungal infections.

Contact Information

Formerly Known As
GR-2397
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Industrial Chemicals
Other Chemicals and Gases
Acquirer
Basilea Pharmaceutica
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gravitas Therapeutics (BAL2062) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gravitas Therapeutics (BAL2062)‘s full profile, request access.

Request a free trial

Gravitas Therapeutics (BAL2062) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gravitas Therapeutics (BAL2062)‘s full profile, request access.

Request a free trial

Gravitas Therapeutics (BAL2062) FAQs

  • Where is Gravitas Therapeutics (BAL2062) headquartered?

    Gravitas Therapeutics (BAL2062) is headquartered in .

  • What industry is Gravitas Therapeutics (BAL2062) in?

    Gravitas Therapeutics (BAL2062)’s primary industry is Buildings and Property.

  • Is Gravitas Therapeutics (BAL2062) a private or public company?

    Gravitas Therapeutics (BAL2062) is a Private company.

  • What is Gravitas Therapeutics (BAL2062)’s current revenue?

    The current revenue for Gravitas Therapeutics (BAL2062) is .

  • Who are Gravitas Therapeutics (BAL2062)’s investors?

    Gravitas Therapeutics has invested in Gravitas Therapeutics (BAL2062).

  • When was Gravitas Therapeutics (BAL2062) acquired?

    Gravitas Therapeutics (BAL2062) was acquired on 22-Dec-2023.

  • Who acquired Gravitas Therapeutics (BAL2062)?

    Gravitas Therapeutics (BAL2062) was acquired by Basilea Pharmaceutica.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process